NCT06875219Active, not recruiting
To Evaluate Long- Term Safety and Efficacy of Luspatercept
An Observational Study to Evaluate Long- Term Safety and Efficacy of Luspatercept in Subjects with Transfusion Dependent Who Received the First Dose of Luspatercept After Its Introduction in the Clinical Practice
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
An observational study to evaluate long-term safety and efficacy of luspatercept in subjects with transfusion dependent who received the first dose of luspatercept after its introduction in the clinical practice
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 350 (actual)
- First submitted
- 25 Feb 2025
- Start date
- 30 Apr 2023
- Primary completion date
- 24 Feb 2025
- Lead sponsor
- Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia
- Diseases
- Thalassaemia
- NCT number
- NCT06875219
What you commit to
- Study type: Observational
- Participants enrolled: 350
- From 30 Apr 2023 to the primary completion date, 24 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who received luspatercept after participating in the "compassionate" use program
Other
- Subjects unwilling to sign informed consent
Who the study is looking for
- Subjects who received at least one dose of luspatercept after its introduction in the clinical practice
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UniversityCagliari, OspPed Microcitemico, Cagliari Coordinator of this site? Confirm its status | Cagliari | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.